Francisco Silva - 14 Feb 2025 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director
Signature
/s/ Francisco Silva
Issuer symbol
BRTX
Transactions as of
14 Feb 2025
Net transactions value
$0
Form type
4
Filing time
19 Feb 2025, 16:25:00 UTC
Previous filing
10 Apr 2024
Next filing
20 Oct 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BRTX Common Stock 155,759 14 Feb 2025 Direct
holding BRTX Common Stock 12,136 14 Feb 2025 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRTX Stock Option Award $0 +768,979 $0.000000 768,979 14 Feb 2025 Common Stock 768,979 $2.46 Direct F4
holding BRTX Stock Option 6 14 Feb 2025 Common Stock 6 $3000.00 Direct F1
holding BRTX Stock Option 15 14 Feb 2025 Common Stock 15 $3000.00 Direct F1
holding BRTX Stock Option 20 14 Feb 2025 Common Stock 20 $3000.00 Direct F1
holding BRTX Stock Option 25 14 Feb 2025 Common Stock 25 $3000.00 Direct F1
holding BRTX Stock Option 293,479 14 Feb 2025 Common Stock 293,479 $5.08 Direct F1
holding BRTX Stock Option 42,059 14 Feb 2025 Common Stock 42,059 $5.08 Direct F1
holding BRTX Stock Option 106,762 14 Feb 2025 Common Stock 106,762 $2.91 Direct F2
holding BRTX Stock Option 394,737 14 Feb 2025 Common Stock 394,737 $1.45 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is currently exercisable.
F2 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F3 The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
F4 The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.